• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

7.945 -0.075 (-0.94%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Verrica Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
January 07, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
November 24, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
November 14, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
November 10, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
October 24, 2025
From Halper Sadeh LLC
Via Business Wire
News headline image
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
October 20, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 07, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
September 19, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 02, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
August 12, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
August 06, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
July 09, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
July 01, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
May 28, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
May 13, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
May 07, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
April 30, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
April 07, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
April 02, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
March 26, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
March 11, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
March 03, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
February 25, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
February 18, 2025
Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause for... 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference
January 21, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Provides Business and Operational Update
December 20, 2024
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 09, 2024
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
December 06, 2024
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Announces Pricing of $42.0 Million Public Offering
November 21, 2024
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap